Hoertel Nicolas, Cipel Hélène, Blanco Carlos, Oquendo Maria A, Ellul Pierre, Leaune Edourd, Limosin Frédéric, Peyre Hugo, Costemale-Lacoste Jean-François
Université de Paris, Faculté de Santé, UFR de Médecine, Paris, France; AP-HP, Hôpital Corentin-Celton, DMU Psychiatrie et Addictologie, Département de Psychiatrie, France; INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Paris, France.
Université de Paris, Faculté de Santé, UFR de Médecine, Paris, France.
J Psychiatr Res. 2021 Apr;136:224-235. doi: 10.1016/j.jpsychires.2021.01.045. Epub 2021 Feb 3.
It remains unclear whether the dopaminergic and noradrenergic systems may be implied in suicide attempt risk. In addition, although the serotonergic system has been extensively studied, no formal meta-analysis has been performed to examine its association with suicide attempt.
Using PRISMA methodology, we performed a systematic literature review and random-effects meta-analyses of the differences in cerebrospinal fluid (CSF) levels of 5-HIAA, HVA and MHPG between suicide attempters and individuals who never attempted suicide.
We identified 30 studies including 937 suicide attempters and 1128 non-attempters; 29 of them measured CSF levels of 5-HIAA, 22 measured CSF levels of HVA and 14 measured CSF levels of MHPG. CSF levels of 5-HIAA and HVA were significantly lower in suicide attempters than in non-attempters [SMD = -0.43 (95% CI: -0.71 to -0.15; p < 0.01) and SMD = -0.45 (95% CI: -0.72 to -0.19; p < 0.01), respectively]. We did not find a significant association between CSF MHPG levels and suicide attempt.
Our analyses relied on a limited number of studies of good quality and most studies included small sample sizes.
Both serotonin and dopamine systems may play a role in suicide attempt risk. Our findings suggest that a silo approach to biomarkers should be phased out in favor of the study of multiple systems in parallel and in the same populations to progress in the identification of the biological components independently associated with suicide risk, with the goal of identifying new treatment targets and improving suicide risk prediction.
目前尚不清楚多巴胺能系统和去甲肾上腺素能系统是否与自杀未遂风险有关。此外,尽管血清素能系统已得到广泛研究,但尚未进行正式的荟萃分析来检验其与自杀未遂的关联。
我们采用PRISMA方法,对自杀未遂者与从未自杀者脑脊液(CSF)中5-羟吲哚乙酸(5-HIAA)、高香草酸(HVA)和3-甲氧基-4-羟基苯乙二醇(MHPG)水平的差异进行了系统的文献综述和随机效应荟萃分析。
我们纳入了30项研究,其中包括937名自杀未遂者和1128名非自杀未遂者;其中29项研究测量了CSF中5-HIAA的水平,22项研究测量了CSF中HVA的水平,14项研究测量了CSF中MHPG的水平。自杀未遂者CSF中5-HIAA和HVA的水平显著低于非自杀未遂者[标准化均数差(SMD)分别为-0.43(95%可信区间:-0.71至-0.15;p<0.01)和-0.45(95%可信区间:-0.72至-0.19;p<0.01)]。我们未发现CSF中MHPG水平与自杀未遂之间存在显著关联。
我们的分析依赖于数量有限的高质量研究,且大多数研究样本量较小。
血清素系统和多巴胺系统可能都在自杀未遂风险中起作用。我们的研究结果表明,应逐步淘汰针对生物标志物的单一研究方法,转而在同一人群中并行研究多个系统,以推进对与自杀风险独立相关的生物学成分的识别,目标是确定新的治疗靶点并改善自杀风险预测。